New pages
Jump to navigation
Jump to search
29 April 2026
- 16:0416:04, 29 April 2026 Hibatullah Abdul Aleem (hist | edit) [272 bytes] Hiba Tullah (talk | contribs) (Created page with "__NOTOC__ ==Hibatullah Abdul Aleem== '''Hibatullah Abdul Aleem''' <br />Contact:<br /> Email: [mailto:dr.hibatullah8@gmail.com]<br /> ==Current Position== ==Professional Background== ==Education== M.B.B.S fron Shadan Institute Of Medical Sciences ==Brief Biography==")
- 10:0210:02, 29 April 2026 SANDBOX:HT (hist | edit) [11 bytes] Hiba Tullah (talk | contribs) (Created page with "HEADING")
25 April 2026
- 03:2003:20, 25 April 2026 Datopotamab deruxtecan-dlnk (hist | edit) [34,560 bytes] Anum Ijaz (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AIJ}} |genericName=DATROWAY |aOrAn=a |drugClass=Trop-2-directed antibody and topoisomerase inhibitor conjugate |indicationType=treatment |indication=DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: 1. Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) DATROWAY is indicated for the treatment of adult patients with locally advanced or metastati...")